EPCC hosted 'Hack the Border 4.0' with competitions and workshops focused on AI, cybersecurity, and data analytics, aiming to give students practical skills relevant to industry demands.

Ohio REACH is aiding foster youth in higher education, as success stories and initiatives to support these students, including emergency funds, emerge alongside concerns about foster care challenges.

Houston broke ground on a VA‑campus disease‑testing lab officials say will process thousands of samples daily, a project that moved forward after federal funding was cut.

The University of Cincinnati leads a trial to test oral TXA's effects on ACL surgery recovery in young athletes, potentially improving rehab outcomes.

University of Cincinnati biologists discovered monk parakeets use cautious strategies to avoid conflict when meeting new flock members, potentially offering insights into social dynamics across species.

GE HealthCare will buy Montreal-based Intelerad for $2.3 billion in cash to expand cloud and AI imaging tools. The deal is expected to close in the first half of 2026.

Seven UH Mānoa students topped a global NeurIPS data‑curation challenge, boosting a model’s accuracy by ~7% using just 1,000 curated examples and earning a NeurIPS podium slot.

Houston Independent School District introduces a secure version of ChatGPT designed to help teachers with administrative tasks without changing teaching methods or curriculum.

Bronx high school students create a bodega-themed escape room, showcasing community culture and their robotics skills.

A UTHealth Houston‑led trial finds the oral GLP‑1 pill orforglipron produced dose‑dependent weight loss and improved blood sugar in adults with type 2 diabetes.

ORNL's National Neutron Scattering School hosted 50 postgraduate students for a comprehensive curriculum on neutron scattering techniques, with lectures and hands-on experiments at SNS and HFIR facilities.

ORNL honored individuals and teams for their contributions to science, technology, and operations at its annual Awards Night, with notable mentions for Brenden Ortiz and the Polyglot Detection Team.

The FDA approved AbbVie and Genmab’s Epkinly with rituximab and lenalidomide after a Phase 3 trial showed large, durable responses in relapsed follicular lymphoma. The label includes boxed warnings for CRS and ICANS.